Expertise
Dr. Franzmann's group has invented an inexpensive and noninvasive oral rinse screening test that helps distinguish individuals harboring molecular features associated with oral cancer from the billions at risk of disease due to tobacco, alcohol, and the HPV virus. Her research interests include human oral cancer risk, prevention, and treatment. Her researchers focus on characterizing salivary molecular markers for application as inexpensive and noninvasive early detection tests and investigating CD44 as a potential target for oral cancer therapy.
Early detection of head and neck cancer and skull base tumors. All cancer and benign tumors of the head and neck including skin, oral cavity, pharynx and larynx, thyroid, sinuses and salivary glands.